LCM Extends Northleaf Covenant Waiver to September 30 as Strategic Review Continues
Litigation Capital Management has secured another one-month extension of the covenant waiver on its debt facility with Northleaf Capital Partners, moving the expiry from 31 August to 30 September 2026.
As reported by Investegate, the AIM-listed funder told the market that the commercial terms are unchanged from the original waiver. Loan interest remains increased by 2.00% per annum for the duration of the waiver period, and there is no additional one-time waiver fee attached to this extension.
LCM said the extension reflects "Northleaf's ongoing support while LCM works towards a long-term resolution of its capital position." The company added that the Strategic Review first announced on 15 September 2025 "continues to progress," and that it will provide an update on that process in due course.
The announcement is the latest in a rolling series of short extensions that has run since December 2025, with each successive waiver granted for roughly a month at a time. The pattern has become the clearest public marker of where LCM stands with its lender: Northleaf has repeatedly declined to call the covenants, but has also declined to grant relief on anything longer than a monthly horizon.
The sequence has not been uneventful. Earlier extensions were accompanied by warnings of negative developments on case investments and expected material write-downs, and in July the company disclosed that permission to appeal in a competition claim had been rejected.
For a funder whose balance sheet depends on the timing of case resolutions, the repeated one-month cadence leaves the underlying question unresolved: whether the Strategic Review produces new capital, a sale, or a run-off.

